JD Health (SEHK:6618) Stock Marks Nine Straight Quarters Of Margin Gains

Simply Wall St.

Aug 16

JD Health International stock has barely moved over the past week, yet the latest half year numbers tell a more energetic story. Revenue reached RMB 40.9b and non IFRS operating income hit RMB 3.5b, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2659176018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659176018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659176018?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","is_english":true,"pubTime":"2026-08-16 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659176018","market":"nz","top_or_hot":-1,"title":"JD Health (SEHK:6618) Stock Marks Nine Straight Quarters Of Margin Gains","media":"Simply Wall St.","content":"<div>\n<p>JD Health International stock has barely moved over the past week, yet the latest half year numbers tell a more energetic story. Revenue reached RMB 40.9b and non IFRS operating income hit RMB 3.5b, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-stock-marks-nine-straight-quarters-of-mar\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health (SEHK:6618) Stock Marks Nine Straight Quarters Of Margin Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health (SEHK:6618) Stock Marks Nine Straight Quarters Of Margin Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-16 04:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-stock-marks-nine-straight-quarters-of-mar><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JD Health International stock has barely moved over the past week, yet the latest half year numbers tell a more energetic story. Revenue reached RMB 40.9b and non IFRS operating income hit RMB 3.5b, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-stock-marks-nine-straight-quarters-of-mar\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1142","symbol_name":"互联网与直销零售","start_time":0,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-stock-marks-nine-straight-quarters-of-mar","article_id":"2659176018","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-stock-marks-nine-straight-quarters-of-mar","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659176018","pubTimestamp":1786826104,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"JD Health International stock has barely moved over the past week, yet the latest half year numbers tell a more energetic story. Revenue reached RMB 40.9b and non IFRS operating income hit RMB 3.5b, which pushed the non IFRS operating margin to 8.5%. That keeps a nine quarter streak of margin gains intact.\nThe market seems to be treating this as just another steady update. The main takeaway is that JD Health International continues to widen its profitability cushion while sitting on RMB 71.5b...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK1142":"互联网与直销零售","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1591":"就地过年概念","BK1615":"港股-互联网","BK1247":"药品零售","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","LU0051755006.USD":"摩根大通中国A (dist)","BK1583":"高瓴概念","BK1571":"互联网医疗","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1589":"北水核心资产","BK1515":"抗疫概念","06618":"京东健康"},"translate_title":"京东健康 (SEHK:6618) 股票连续九个季度利润率增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.98},"content_text":"JD Health International stock has barely moved over the past week, yet the latest half year numbers tell a more energetic story. Revenue reached RMB 40.9b and non IFRS operating income hit RMB 3.5b, which pushed the non IFRS operating margin to 8.5%. That keeps a nine quarter streak of margin gains intact. The market seems to be treating this as just another steady update. The main takeaway is that JD Health International continues to widen its profitability cushion while sitting on RMB 71.5b of cash and equivalents. The gap between that earnings momentum and a 20.1x P/E will be front of mind from here. Love JD Health International's rising non IFRS margin and sizeable cash cushion, but unsure how its 20.1x P/E stacks up against peers? Compare it with other companies that pair earnings strength with balance sheet support in our list of solid balance sheet and fundamentals stocks (434 results). AdvertisementH1 2026 Earnings Summary  Revenue (H1 2026 vs H1 2025): RMB 40,887.884m vs. RMB 35,290.047m (up about 15.8%) Net Income excl. Extra Items (H1 2026 vs H1 2025): RMB 3,436.804m vs. RMB 2,596.445m (up about 32.4%) Basic EPS (H1 2026 vs H1 2025): RMB 1.081562 vs. RMB 0.821568 (up about 31.6%) Non IFRS Operating Margin (H1 2026 vs H1 2025): 8.5% vs. 7.0% (expanded about 1.5 percentage points, with 9 consecutive quarters of year-on-year improvement)  Tired of scrolling through dense earnings tables and margin figures for JD Health International? See a clear visual picture of how the company’s valuation lines up with its growth in our company report for JD Health International.. SEHK:6618 Trailing 12-Month Earnings & Revenue History as at Aug 2026 JD Health’s Margin Story Is Hitting Its Marks The bullish pitch around JD Health International is that omnichannel scale and AI should steadily lift margins while services become a larger earnings engine. The latest half year results give that view some hard evidence. Non IFRS operating margin reached 8.5% with nine straight quarters of year on year gains, which fits a narrative of improving operating leverage rather than one off cost cuts. Service revenue of RMB 7.0b is rising as a share of the total and is backed by concrete milestones. The “Dr. Da Wei” AI doctor has grown its user base multiple times over and is already embedded in consultations and conversions, even if monetization is still early. Fulfillment expense as a ratio of revenue is flat at about 10%, which suggests JD Health is holding the line on its dependence on JD.com logistics while letting procurement and mix do more of the margin work. See how that 8.5% non IFRS operating margin, growing service contribution and stable fulfillment ratio line up with institutional expectations by checking the consensus price target analysis for JD Health International. JD Health Bear Case Meets Regulatory And AI Reality The bearish view is that JD Health faces rising regulatory and AI compliance costs that could eventually squeeze margins and cash generation. The latest half year results do not fully support that yet, but they also do not clear the risks. Gross margin is 26.1% and non IFRS operating margin is 8.5%, with fulfillment at about 10% of revenue. That suggests regulatory scrutiny in nutrition and supplements is a drag on growth mix, not yet a visible hit to group level profitability. However, AI products such as “Dr. Da Wei” are still largely non commercial and management openly flags uncertainty around the timing of meaningful AI revenue. With medical devices growing slower than other segments and nutrition under regulatory pressure, the feared mix and policy headwinds are present, just partially masked for now by procurement gains and cost discipline. With JD Health International trading at a premium industry P/E and a DCF estimate far above the current HK$39.5 share price, you need to verify whether the balance sheet truly supports that gap. Check the full liquidity, debt and cash runway breakdown in our financial health analysis of JD Health International stock. Own Your Next Investment Move If JD Health International’s rising non IFRS margin and sizeable cash position have your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch for a more appealing entry point. Once you are invested, use the Portfolio Command Center to cut through noise and see the key earnings, valuation and risk updates that matter for your holdings. For a broader view on JD Health International and similar stocks, tap into the Community and compare your thinking with thousands of other investors. This way you can spot hidden catalysts or emerging risks earlier and stay informed about developments in the market. Curious About Alternatives Beyond JD Health? Fresh stock ideas can move from quiet accumulation to breakout momentum faster than most investors react. Scan these under the radar lists before the crowd catches on and get in early.  Spot potential breakout compounders by reviewing the 612 high quality undiscovered gems while they are still flying under most radars and pricing has not fully caught up yet. Target balance sheet resilience and earnings support by filtering for companies in the list of solid balance sheet and fundamentals stocks (434 results) before shifting sentiment drops weaker stocks and widens quality gaps. Ride the growing demand for AI infrastructure by scanning the 55 AI infrastructure stocks while these suppliers remain under the radar for now and institutional money has not fully piled in.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}